Introduction
The development of abdominal aortic aneurysms (AAAs) involves extensive infiltration of inflammatory cells-such as macrophages, neutrophils, T cells, and mast cells-that are recruited from the lumen or the vasa vasorum. Mast cells are abundant in both the adventitia and the media in human AAA lesions 1, 2 and correlate positively and significantly with AAA maximal diameter. 3, 4 In ruptured human
AAAs, mast cells dwell in the adventitia and media and often colocalize with macrophages and T cells, 5 -7 suggesting their interplay in AAA lesions. AAA lesions also contain more activated mast cells than do normal aortas or atherosclerotic lesions. 2 After activation, mast cells release cytokines, chemokines, and proteases to mediate consequent inflammatory cell recruitment, neighbouring cell protease expression and activation, angiogenesis, and apoptosis. Angiogenesis is a central process of AAA pathogenesis, 8 and associates closely with AAA rupture. 9 In human AAA lesions, many mast cells in the media and adventitia correlate with densities of neovascularization. 3 Inflammatory responses in human AAAs also associate with arterial cell apoptosis. 6, 10 Mast cells release chymase to inactivate † These authors contributed equally to the study.
the focal adhesion kinase-mediated smooth-muscle cell (SMC) survival signalling or to release tumour necrosis factor-a (TNF-a), which binds to the 'death receptors' on the surface of endothelial cells (ECs) and induces caspase-dependent EC apoptosis. 11, 12 Mast cells also release chymase to degrade SMC fibronectin, inhibit SMC collagen synthesis, and activate caspases; they also release transforming growth factor-b1 from extracellular matrix to disrupt SMC adhesion and inhibit SMC proliferation and growth, thereby promoting SMC apoptosis. 13, 14 Several experimental AAA models recently have examined the direct participation of mast cells in AAA pathogenesis. In aortic elastase perfusion-induced and peri-aortic CaCl 2 injury-induced AAA, all C57BL/6 wild-type (WT) mice developed AAA lesions, but mast cell-deficient Kit W-sh/W-sh mice under the same genetic background
were fully protected at any tested time point. 15 Reduced AAA in Kit W-sh/W-sh mice accompanied impaired internal elastic lamina degradation, decreased numbers of macrophages, CD3 + T lymphocytes, SMCs, apoptotic cells, and CD31 + microvessels, and decreased levels of aortic tissue interleukin-6 (IL-6) and interferon-g (IFN-g).
Activation of mast cells in WT mice with compound 48/80 enhanced AAA growth, while mast cell stabilization with cromolyn diminished AAA formation, suggesting the importance of mast cell granule release to AAA pathogenesis. Mechanistically, we demonstrated that mast cells release pro-inflammatory IL-6 and IFN-g to stimulate vascular wall elastinolytic cathepsin and matrix metalloproteinase (MMP) expression. 15, 16 In peri-aortic CaCl 2 -induced AAA in rats, total mast cells and activated mast cells were increased over time (3, 7 , and 14 days post-CaCl 2 ). Mast cell-deficient Ws/Ws rats also failed to develop AAA. 2 Although lesion macrophage contents were not affected, lesion T-cell accumulation was fully blocked in Ws/Ws rats. Ws/Ws rats also showed reduced MMP-2 and MMP-9 activities and capillary density. 2 In the same experimental AAA, mast cell inactivation with Tranilast completely blocked AAA formation and reduced lesion mast cell and T-cell numbers, capillary density, and MMP-2 and MMP-9 activities.
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Leucocyte migration to the site of inflammation in the arterial wall is essential to AAA pathogenesis. Deficiency of the chemokine leukotriene B4 receptor BLT1 in apolipoprotein E-deficient (Apoe -/ -) mice reduced angiotensin-II (Ang II) infusion-induced AAAs in mice. AAA lesions from these mice contained significantly lower numbers of Mac-3 + macrophages and CD4 + T cells than did AAA lesions from Apoe -/ -control mice. 17 In the same Apoe -/ -mice, transplantation of bone-marrow cells from chemokine (C-C motif) receptor 2 (CCR2)-deficient mice reduced Ang II-induced AAA and atherosclerosis and impaired Mac-3 + macrophage accumulation and inflammatory cytokine production in these lesions. 18 These observations suggest that BLT1, CCR2, and possibly other chemokine receptors on macrophages are required for their migration into AAA and atherosclerotic lesions. For example, expression of eotaxin and its receptor CCR3 were increased in human atherosclerotic lesions. 19 Absence of chemokine monocyte chemoattractant protein-1 (MCP-1) 20 or its receptor, CCR2, 21 reduced atherosclerosis in mice, supporting the importance of CCR2 and CCR3 in leucocyte accumulation during atherogenesis. We do not know exactly which chemokine(s) mast cells use for their migration into AAA lesions, but many direct and indirect studies suggest that mast cell accumulation in AAA lesions may enhance recruitment of subsequent inflammatory cells. We showed that mast cells release TNF-a to stimulate the expression of adhesion molecules, including intercellular adhesion molecule-1, vascular cell adhesion molecule-1, P-selectin, and Eselectin from mouse aortic ECs, and enhance neutrophil adhesion. 27 and those of our earlier studies. 28 The percentage of incidence per group was determined, and aortas were graded. The maximal diameter of each aneurysm was measured after the peri-adventitial tissue was carefully removed from the aortic wall. All animal procedures conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Harvard Medical School Standing Committee on Animals (protocol # 03759).
BMMC culture and BMMC reconstitution
Ccr2 -/ -mice (C57BL/6, N9) were purchased from The Jackson Labora- 
Immunohistochemical analysis
All aortas were embedded with OCT for immunohistochemical analysis as described previously. 15, 16 Aorta segments for immunohistochemistry were cut from the maximal external aneurysm diameter. Slides of each sample from identical levels were used for staining with each antibody. Serial cryostat cross-sections (6 mm) were used for immunostaining for macrophages (Mac-3 
Real-time polymerase chain reaction (RT-PCR)
Total cellular RNA was extracted from BMMC from Apoe -/ -and Apoe -/ -Ccr2 -/ -mice using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The RNA samples were then treated with an RNase-free DNase (Ambion, Carlsbad, CA, USA) to remove genomic DNA contaminants. Equal amounts of RNA were reverse transcribed, and quantitative PCR was performed in a single-colour real-time polymerase chain reaction (RT-PCR) detection system (Stratagene, La Jolla, CA, USA). The mRNA levels of CCR2, CCR3, BLT1, and BLT2 were normalized to those of b-actin.
Statistical analysis
Because of relatively small sample sizes and data distribution abnormality, we selected the non-parametric Mann-Whitney U-test for non-paired data sets and the Wilcoxon signed-rank test for paired data sets to examine statistical significance throughout this study. P , 0.05 was considered statistically significant.
Results

Mast cell deficiency reduces Ang II infusion-induced AAA formation in mice
We previously showed that the absence of mast cells protected mice from the formation of both aortic elastase perfusion-induced and peri-aortic CaCl 2 injury-induced AAAs. 15 Using Apoe -/ -and Apoe -/ -Kit W-sh/W-sh littermate mice, we demonstrated that mast cell deficiency also reduced Ang II chronic infusion-induced experimental AAAs. According to a prior grading system used broadly in this experimental model, 27, 28 we found that the majority of Apoe -/ -Kit W-sh/W-sh mice had T0 lesions, whereas a much higher percentage of the Apoe -/ -mice developed T3 and T4 lesions ( Figure 1A ). Figure 1A and B). BMMC reconstitution did not affect luminal aortic diameters ( Figure 1C) . These results suggest that mast cell migration to AAA lesions is important to AAA formation and that CCR2 mediates mast cell migration.
3. (Figure 2A) . CCR2 deficiency in BMMC may affect the expression of other chemokine receptors. Impaired mast cell infiltration ( Figure 2A ) and reduced AAA formation ( Figure 1A and B support the hypothesis that CCR2 mediates mast cell migration to AAA lesions in Ang II-induced experimental AAA.
Mast cell deficiency attenuates AAA lesion inflammation
Mast cells release TNF-a and tryptase to stimulate EC adhesion molecule expression and leucocyte adhesion and migration. 22, 23 The absence of mast cells therefore should reduce AAA lesion leucocyte accumulation and inflammation-important mechanisms leading to impaired AAA growth. AAA lesion section immunostaining demonstrated significant reduction in lesion chemokine MCP-1 levels ( Figure 3A) , adventitia Mac-3 + macrophage-positive areas ( Figure 3B ), CD8 + T-cell numbers ( Figure 3C ), CD4 + T-cell numbers ( Figure 3D) , and MHC class II-positive areas (Supplementary material online, Figure S1 ). These observations suggest that mast cell accumulation in AAA lesions is essential to the recruitment of other inflammatory cells (e.g. macrophages, T cells). Similar to AAA lesion sizes ( Figure 1A Figure S1 ). Lesion leucocyte recruitment therefore may require CCR2-mediated mast cell accumulation in AAA lesions.
Mast cell deficiency impaired AAA lesion angiogenesis, lesion cell apoptosis, and proliferation
We have previously shown that mast cells use chymase to promote angiogenesis. 15, 34 These cells also produce IL-6, IFN-g, chymase, and tryptase to induce aortic SMC apoptosis. 15 (scale bar: 100 mm) are indicated to the right. Experimental group denotations are the same as in Figure 2 .
CCR2 mediates mast cell migration
Apoe -/ -Kit W-sh/W-sh mice receiving BMMC from Apoe -/ -Ccr2 -/ -mice, also had significantly reduced TUNEL-positive apoptotic cells in the media ( Figure 5A ) and adventitia (
Figure 5B Figure 5C ). Mast cell-derived chemokines such as MCP-1 also promote the proliferation of arterial leucocytes and SMCs. 37, 38 In a femoral artery injury model, CCR2 deficiency decreased intima hyperplasia, establishing an important role of CCR2 in SMC proliferation. 39 Mast cells also mediate inflammatory cell activation and proliferation through direct cell-cell interaction. 40 Reduced cell proliferation ( Figure 5C ) in AAA lesions from mast cell-deficient mice, or those with low numbers of mast cells, therefore may result in part from low chemokine levels in these lesions ( Figure 3A ).
Mast cell deficiency impairs AAA lesion elastin fragmentation and medial SMC loss
One of the most important features of human and animal AAA is medial elastin degradation, mediated by elastases, including MMPs and cathepsins. 41 -43 Mast cells are rich reservoirs of these proteases 15 in addition to their unique proteases, such as chymase, which also has elastinolytic activities. 44 Lack of mast cells in 
Discussion
This study provided evidence from experimental AAAs that mast cells participate importantly in AAA formation in mice, and that mast cell migration to AAA lesions relies on the expression of the mast cell surface chemokine MCP-1 receptor CCR2. The absence of mast cells protected Apoe -/ -mice from Ang II infusion-induced AAAs, and deficiency of CCR2 on mast cells reduced mast cell recruitment into AAA lesions; blocked consequent accumulation of lesion Mac-3 + macrophages, CD4 + and CD8 + T cells; and failed to restore reduced AAA formation in mast cell-deficient mice.
Leucocyte migration and accumulation in atherosclerotic plaques, 16 AAA lesions, 15 and white adipose tissue in obese subjects 44 are important in disease pathogenesis. We have been interested in which inflammatory cells appear first in these inflammatory lesions, and whether and how they recruit subsequent inflammatory cells. Although we do not know whether mast cells are the first inflammatory cells at the site of inflammation, they seem to appear before macrophages and T cells. In white adipose tissue, deficiency or pharmacological stabilization of mast cells prohibited macrophage accumulation. 44 In this study, the absence of mast cells also reduced macrophage and CD4 + and CD8 + T-cell accumulation in AAA lesions. Once mast cells failed to infiltrate into AAA lesions due to the lack of MCP-1 receptor CCR2, infiltration of macrophages and T cells was also blocked, suggesting that mast cells are essential in recruiting other inflammatory cells.
This study left at least two fundamental questions unresolved. First, we showed that CCR2 deficiency in mast cells did not affect the CCR2 mediates mast cell migration expression of CCR3 or BLT1, and even increased the expression of BLT2. These observations support the hypothesis that mast cell migration uses CCR2 in this experimental AAA model. Mast cells lacking CCR3, BLT1, or BLT2, however, also may exhibit delayed infiltration. Mast cell infiltration into AAA lesions therefore may also use other chemokines, such as eotaxin or leukotriene; our study did not exclude these possibilities. Second, this study, and earlier studies by us and by others, 2, 15, 16, 44 suggested that mast cell accumulation to the site of inflammation in AAAs, atherosclerosis, and adipose tissue is essential to consequent cell infiltration. Depletion of T cells 45 -47 or neutrophils 48 reduced macrophage and T-cell infiltration into AAA lesions, atherosclerotic lesions, and white adipose tissue, thereby protecting experimental animals from AAA, atherosclerosis, and obesity. It is possible that depletion of T cells or neutrophils also affects mast cell infiltration to AAA lesions. None of these studies, however, examined this possibility. Like many other chemokine receptors, CCR2 is a heterotrimeric G protein-coupled receptor that mediates MCP-1-induced leucocyte signalling. In macrophages, MCP-1 binding on CCR2 leads to immediate phosphorylation of p42/p44 (mitogen-activated protein kinases) MAPK, c-Jun N-terminal kinases, Lyn, Janus kinase 2 (JAK2), and cytoskeleton-binding protein paxillin followed by association of CCR2 with Lyn and paxillin and activation of downstream transcription factors c-Jun, signal transducer and activator of transcription (STAT)-3, and STAT-5. 49, 50 Tyrosinephosphorylated proteins localize together with actin filament at the macrophage focal adhesion points. 49 The same signalling pathways were detected in monocytes and CCR2-transfected human embryonic kidney 293 cells. 51 Although not tested in this study, mast cells may also use these signalling pathways for their migration and accumulation in AAA lesions. This hypothesis is consistent with earlier observations that bone-marrow-derived macrophages from Apoe -/ -Ccr2 -/ -mice showed significantly delayed accumulation in Ang II-induced AAA lesions compared with those from Apoe -/ --mice. 18 Both macrophages and mast cells use CCR2 for their migration and accumulation in Ang II-induced AAA lesions. In this study, we proposed that the absence of mast cells or defective mast cell infiltration reduced AAA lesion angiogenesis (Figure 4) , lesion cell apoptosis and proliferation ( Figure 5) , and medial elastin degradation and SMC loss ( Figure 6 ). Although mast cells help promote angiogenesis, cell apoptosis, protease expression and secretion, the phenotypes presented in Figures 4 -6 also can be secondary to reduced inflammatory cell infiltration and impaired AAA lesion formation. T cells and macrophages are rich in inflammatory cytokines, growth factors, and proteases that act similarly to mast cells. Reduced lesion angiogenesis, lesion cell apoptosis and cell proliferation, and AAA medial elastin degradation and SMC loss, therefore, can result from the combined loss of mast cells and reduction in macrophages, T cells, and other untested inflammatory cells. Regardless of whether the reduced AAA in Apoe -/ -Kit W-sh/W-sh mice receiving
BMMCs from Apoe -/ -Ccr2 -/ -mice was due to reduced accumulation of mast cells or consequently inflammatory macrophages and T cells (Figure 3) , pharmacological blockade of CCR2 with its antibodies or antagonists may affect infiltration of mast cells and other inflammatory cells into human AAA lesions, thereby preventing or reducing human AAA formation or progression. This possibility has been tested in several other experimental inflammatory diseases and in human clinical trials. In mouse experimental collagen-induced rheumatoid arthritis, CCR2-neutralizing antibody MC-21 reduced disease severity significantly. 52 Similarly, human CCR2 blocking antibody (MLN1202) has been used to treat patients with rheumatoid arthritis. Although MLN1202 did not ameliorate synovial inflammation in active rheumatoid arthritis, this antibody greatly reduced free CCR2 on the surface of peripheral blood monocytes. 53 In an experimental mouse model of Porphyromonas gingivalis infection-induced periodontitis, CCR2 antagonist (JNJ-17166864) treatment significantly reduced the area of alveolar bone loss. 54 Johnson & Johnson recently completed a randomized, blinded, placebo-controlled, parallel-group, two-centre outpatient study to test the efficacy of this CCR2 antagonist on patients with symptoms of seasonal allergic rhinitis, which was improved by 16% or greater (ClinicalTrials.gov Identifier: NCT00604123). JAK2 phosphorylation of CCR2 associates with Ca 2+ mobilization. 51 MCP-1 sensitized neurons or non-neuronal cells from rat spinal cords showed increased MCP-1 concentrationdependent Ca 2+ , which was abolished by AZ889-a CCR2 antagonist that diminishes chronic constriction injury-induced neuropathic pain in rats. 55 This AstraZeneca compound has also been used in clinical trials for rheumatoid arthritis and chronic obstructive pulmonary disease. The CCR2 antagonist MK-0812 can efficiently block monocyte migration to the skin of rhesus monkeys in a delayed-type hypersensitivity reaction model. 56 This Merck compound has been assessed in a clinical trial for patients with multiple sclerosis (ClinicalTrials.gov Identifier: NCT00239655). Indeed, there are many other CCR2 antibodies or antagonists undergoing clinical trials for human diseases, including rheumatoid arthritis, multiple sclerosis, chronic pain, lupus, restenosis, and atherosclerosis. 57 These CCR2 antagonists or antibodies may be effective in blocking mast cell infiltration in human AAA lesions. This study nevertheless establishes a role of mast cells in AAA formation and the involvement of mast cell CCR2 in their infiltration to AAA lesions, and likely in other arterial or non-arterial lesions.
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